Abstract
Purpose: The evidence suggesting increased HAART efficacy over time comes from randomized trials or cohort studies. This retrospective multicenter survey aimed to assess the variation over time in the efficacy and tolerability of first-line HAART regimens in unselected patients treated in ordinary clinical settings. Methods: Retrospective analysis of data of all patients starting first-line HAART regimens in 1998 and 2006 at adhering centers in the Italian CISAI group. Results: For the 543 patients included, mean age was 39.1 ± 9.8y in 1998 and 41.0 ± 10.7y in 2006 (p=0.03), with a similar proportion of males. Baseline mean log10 HIV-RNA was 4.56 ± 0.97 copies/mL in 1998 vs 4.91 ± 0.96 copies/mL in 2006 (p
Original language | English |
---|---|
Pages (from-to) | 32-37 |
Number of pages | 6 |
Journal | Journal of Antivirals and Antiretrovirals |
Volume | 4 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2012 |
Keywords
- AIDS
- HAART
- HAART efficacy
- HAART toxicity
- HIV
- Late hiv presentation
ASJC Scopus subject areas
- Infectious Diseases
- Virology